Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(4 years from now) | |
US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(4 years from now) | |
US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(4 years from now) | |
US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(10 years from now) | |
US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
Orphan Drug Exclusivity (ODE) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 2025-05-14
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by ...
Dosage: SOLUTION;SUBCUTANEOUS
43
United States
14
Japan
14
European Union
9
Australia
8
Spain
8
China
8
Canada
6
Israel
5
Denmark
5
Hong Kong
5
Russia
4
Mexico
4
Brazil
4
Portugal
3
Slovenia
3
Poland
2
Lithuania
2
Hungary
2
Croatia
2
Cyprus
2
RS
1
IB
1
Austria
1
Norway
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic